Trials / Recruiting
RecruitingNCT06430788
A Study of Emapalumab for Pediatric Aplastic Anemia
Phase 2a/2b Study Emapalumab: A Window of Opportunity in Pediatric Aplastic Anemia
- Status
- Recruiting
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 35 (estimated)
- Sponsor
- Memorial Sloan Kettering Cancer Center · Academic / Other
- Sex
- All
- Age
- 0 Years – 25 Years
- Healthy volunteers
- Accepted
Summary
The purpose of this study is to find out whether upfront emapalumab treatment can help in sAA (Aplastic Anemia) treatment planning and increase the effectiveness of standard treatment options. Funding Source- FDA OOPD
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | Emapalumab | Emapalumab is an interferon gamma (IFNγ) blocking antibody |
Timeline
- Start date
- 2024-05-21
- Primary completion
- 2029-05-21
- Completion
- 2029-05-21
- First posted
- 2024-05-28
- Last updated
- 2025-12-17
Locations
6 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT06430788. Inclusion in this directory is not an endorsement.